Chirag Talati

When asked about the Cipla Indore facility, which has come under the USFDA scanner for manufacturing norms violations, Talati reassures that the facility is not a major contributer to Cipla earnings. Hence this news, he feels should not affect sales.

Ranbaxy ban: Outsourcing an option, negative EBIDTA seen

Ranbaxy‘s Toansa plant supplies 70 percent of US-based Ohm Laboratories‘ Active Pharmaceutical Ingredients (API) requirement. This in turn means the company will soon have to go in for outsourcing, incurring a huge costs.

Chirag Talati bullish on Cipla

Chirag Talati, Pharma Analyst at Espirito Santo Securities is bullish on Cipla.

New drug pricing policy: Which cos will be impacted most?

Chirag Talati, Espirito Santo Securities says the policy had been anticipated for long. According to him, Cipla, Cadila and Ranbaxy will be impacted negatively.

Espirito Santo questions Biocon's accounting practices

Espirito Santo has downgraded Bangalore-based Biocon to "sell" from "neutral" and sharply revised its target price to Rs 186 a share from Rs 350, flagging off several issues, which it says raise accounting and corporate governance questions over at the biotech firm.

RBI's rupee move won't impact pharma companies, say experts

Chirag Talati, pharma analyst, Espirito Santo Securities says the RBI's move to boost the Indian currency by asking exporters to convert 50% of their foreign exchange holdings into rupees will not have a significant impact on pharma companies.

USFDA settlement to hit Ranbaxy by Rs 60/sh: Espirito Santo

Ranbaxy Laboratories said it has reached a settlement with the US Food and Drug Administration while setting aside USD 500 million to address its potential liability from a separate US Justice Department investigation.

Espirito Santo Sec's health forecast for 3 pharma stocks

While the market has been weak, the pharma sector has remained steadfastly resilient. Chirag Talati, Pharma Analyst, Espirito Santo Securities talks about what is making news in the pharma space.

Buy Lupin, says Chirag Talati

Buy Lupin, says Chirag Talati, Pharma Analyst, Espirito Santo Securities.

Penalty to wipeout Ranbaxy's gains: Espirito Santo

Pharma stocks reeled under pressure on fears that the duty entitlement passbook (DEPB) benefits scheme may be withdrawn from the exporting companies, thus, hurt their overseas formulations.